Innostellar Biotherapeutics Co.,ltd

This study tests a gene therapy called LX102 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The goal is to see if it is safe and can improve or maintain eyesight, possibly reducing the need for frequent eye injections. About 50 adults…

This early-stage study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes vision loss. The treatment uses a harmless virus to deliver a working copy of the RPE65 gene to the retina. The main goals are to check safety and see if it can impro…

This study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes blindness. 30 participants aged 6 and older were randomly assigned to receive the therapy or no treatment. The goal is to see if the treatment improves functional vision and ligh…